001360.KS
SAMSUNG PHARM. Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 1,330.00
−0.08%Year over year
Reported trailing growth
- Revenue
- -2.4%
- EBITDA
- —
- EBIT
- -9.9%
- EPS
- —
- Free cash flow
- +21.6%
- Operating cash flow
- +25.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.8%
- EBITDA
- -53.9%
- EBIT
- -31.2%
- Net income
- +181.9%
- EPS
- +178.5%
- Free cash flow
- +42.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026